Drug Profile
Research programme: anticancer therapeutics - Mitsubishi Tanabe/Odyssey Thera
Alternative Names: Drug discovery - Mitsubishi Tanabe/Odyssey TheraLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation; Odyssey Thera
- Class Small molecules
- Mechanism of Action Mitosis inhibitors; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 15 May 2009 Early research in Cancer in USA (unspecified route)